

Advisory Committee for Reproductive Health Drugs  
July 19, 1996

0380 '96 JUL 30 A10:54

# **Non-U.S. Clinical Studies**

**Ridgely C. Bennett, M.D., M.P.H.**  
**Medical Officer, DRUDP**

# Proposed Regimen

- ◆ Single oral dose of three 200 mg tablets of mifepristone
- ◆ In two days, two 200 ug tablets of misoprostol, unless confirmed termination

# Studies 14 and 24: Design

	<b>Study 14</b>	<b>Study 24</b>
<b>No. patients</b>	<b>1286</b>	<b>1194</b>
<b>Duration of gestation</b>	<b><math>\leq 49</math> d</b>	<b><math>\leq 63</math> d</b>
<b>Day 1: Mifepristone</b>	<b>600 mg</b>	<b>600 mg</b>
<b>Day 3: Misoprostol</b>	<b>400<math>\mu</math>g</b>	<b>400 <math>\mu</math>g; if no abortion in 3 hours, additional 200 <math>\mu</math>g</b>
<b>Follow-up</b>	<b>Day 8-15</b>	<b>Day 10-18</b>

# Exclusion Criteria

- ◆ Smoke  $\geq$  10 cigarettes/day
- ◆ Cardiovascular disease
- ◆ Asthma
- ◆ Glaucoma or high intraocular pressure
- ◆ Diabetes
- ◆ Hyperlipidemia
- ◆ Renal, adrenal, or hepatic insufficiency
- ◆ Anemia

# Treatment Outcome: Definition

- ◆ **Successful: complete expulsion without need for surgery**
  
- ◆ **Failure:**
  - incomplete expulsion
  - pregnancy continued
  - surgery required for hemostasis

# Efficacy Evaluable Population

## ◆ Pregnancy confirmed

	n/N	%
Study 14	1205/1286	93.7
Study 24	1104/1194	92.5

# Study 14: Treatment Outcome

## Efficacy Evaluable Population

	<b>N</b>	<b>Rate (%)</b>
<b>Complete expulsion</b>	<b>1149</b>	<b>95.4</b>
<b>Incomplete expulsion</b>	<b>34</b>	<b>2.8</b>
<b>Ongoing Pregnancy</b>	<b>18</b>	<b>1.5</b>
<b>Surgery to stop bleeding</b>	<b>4</b>	<b>0.3</b>
<b>Total</b>	<b>1205</b>	

# Study 14

## Complete Expulsion Rate for Efficacy Evaluable Population by Gestational Age

<b>Gestational Age (days)</b>	<b>Events/N</b>	<b>Rate (%)</b>
<b>&lt; 36</b>	<b>117/119</b>	<b>98.3</b>
<b>36-42</b>	<b>447/463</b>	<b>96.5</b>
<b>43-49</b>	<b>570/607</b>	<b>93.9</b>
<b>50-56</b>	<b>12/13</b>	<b>92.3</b>
<b>57-63</b>	<b>3/3</b>	<b>100.0</b>
<b>≤ 49</b>	<b>1134/1189</b>	<b>95.4</b>



# Study 24

## Complete Expulsion Rate for Efficacy Evaluable Population by Gestational Age

<b>Gestational Age (days)</b>	<b>Events/N</b>	<b>Rate (%)</b>
<b>&lt; 36</b>	<b>15/15</b>	<b>100.00</b>
<b>36-42</b>	<b>163/171</b>	<b>95.3</b>
<b>43-49</b>	<b>293/306</b>	<b>95.7</b>
<b>50-56</b>	<b>358/389</b>	<b>92.0</b>
<b>57-63</b>	<b>196/223</b>	<b>87.9</b>
<b>≤ 49</b>	<b>471/492</b>	<b>95.7</b>

# Study 24: Treatment Outcome

## Evaluable Patients with Gestational Age $\leq$ 49 Days

	n	Rate (%)
<b>Total</b>	<b>210</b>	
<b>Misoprostol not administered</b>		
Complete expulsion	19	100.0
<b>Single dose misoprostol</b>		
Complete expulsion	189	99.0
Incomplete expulsion	1	0.5
Surgery to stop bleeding	1	0.5
<b>Complete expulsion rate</b>	<b>208/210</b>	<b>99.0</b>

## Analysis of Success Rates for Subgroups: Studies 14 and 24

Subgroup	Study 14 n/N (%)	Study 24 n/N (%)
<b>If GA ≤ 49 days</b>	<b>1134/1189 (95.4)</b>	<b>471/492 (95.7)</b>
<b>. . and took ≤ 1 misoprostol dose</b>	<b>1134/1189 (95.4)</b>	<b>208/210 (99.0)</b>
<b>. . and known outcome</b>	<b>1160/1216 (95.4)</b>	<b>227/230 (98.7)</b>
<b>. . and if unknown outcome = failure</b>	<b>1160/1264 (91.8)</b>	<b>227/239 (95.0)</b>

10  
11

# Success Rates:

## Studies 14 and 24

	<b>Study 14 (N=1286)</b>	<b>Study 24 (N=1194)</b>
<b>Evaluable (N)</b>	1205	1104
<b>No. of Patients with Success</b>	1149	1025
<b>Rate (%)</b>	95.4	92.8

H  
12

## Adverse Events with Incidence > 2%: Studies 14 and 24

Adverse Event	Incidence (%)	
	Study 14	Study 24
Painful contraction of uterus	78.5	85.6
Nausea	40.7	49.9
Vomiting	16.8	29.1
Diarrhea	12.3	15.4
Headache	2.6	3.1
Dizziness	1.2	2.6
Metrorrhagia	N/A	3.4
Anemia	N/A	2.9

# Cardiovascular Adverse Events

## ◆ Mild to moderate

- tachycardia and palpitations
- hypotension
- hypertension
- syncope

## ◆ Severe

- 1 case hypotension

13  
14

# Serious Adverse Events: Studies 14 and 24

◆ Enrolled	2480
◆ Hospitalizations	21 (1%)
◆ Heavy bleeding	52 (2%)
– surgical intervention	15 (1%)
– blood transfusion	4 (<1%)